Clinical Report: Interdisciplinary Insights into Depression and Breast Cancer

Overview

This review highlights the complex bidirectional relationship between depression and breast cancer, emphasizing how depression can exacerbate cancer progression and clinical outcomes. It also discusses the need for integrated treatment approaches that address both mental health and cancer care.

Background

Depression is a prevalent mental disorder that significantly impacts quality of life and is increasingly recognized as an independent risk factor for breast cancer. Breast cancer remains the most common cancer among women, contributing to high mortality rates. Understanding the interplay between these two conditions is crucial for improving patient outcomes and treatment adherence.

Data Highlights

No specific numerical data or trial data were provided in the source material.

Key Findings

• Depression can lead to dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, resulting in elevated glucocorticoids that may promote breast cancer progression.
• Patients with breast cancer have a depression prevalence rate as high as 32.2%, significantly higher than the general population rate of 6.4%.
• Depression impairs immune function, reducing the effectiveness of immune cells like T cells and natural killer (NK) cells, which may facilitate tumor growth.
• Integrated treatment approaches, including pharmacological and psychological interventions, are necessary for effectively managing the comorbidity of depression and breast cancer.
• Emerging therapies such as traditional Chinese medicine and gut microbiota regulation show potential in addressing neuroimmune dysregulation.

Clinical Implications

Healthcare providers should consider the high comorbidity of depression in breast cancer patients and implement routine screening for depressive symptoms. An interdisciplinary approach that combines psychological and oncological care may enhance treatment adherence and overall patient outcomes.

Conclusion

The interplay between depression and breast cancer necessitates a comprehensive understanding and integrated management strategies to improve clinical outcomes for affected patients.

Related Resources & Content

1. Frontiers in Psychiatry, 2026 -- Exploring the Relationship Between Depression and Diabetes in Women
2. The ASCO Post, 2025 -- Integrating Mental Health Into Cancer Care: A Community Oncology Imperative
3. BMC Psychiatry, 2025 -- Risk prediction models for depression in older adults with cancer
4. The ASCO Post, 2024 -- The Lancet Commission on Breast Cancer: Reducing Overlooked Inequities in Breast Cancer
5. Recommendation: Depression and Suicide Risk in Adults: Screening | United States Preventive Services Taskforce
6. GeroScience, 2025 -- Depression increases cancer mortality by 23–83%: a meta-analysis of 65 studies across five major cancer types
7. Recommendation: Depression and Suicide Risk in Adults: Screening | United States Preventive Services Taskforce
8. Depression increases cancer mortality by 23–83%: a meta-analysis of 65 studies across five major cancer types | GeroScience | Springer Nature Link
9. Table 2. [NCCN (2018). CYP2D6 Phenotypes and Therapeutic Recommendations for Tamoxifen]. - Medical Genetics Summaries - NCBI Bookshelf